Descripción del proyecto
Detección ultrasensible y rápida de la recidiva del cáncer de cabeza y cuello
La recidiva tras la remisión inicial es la principal causa de muerte relacionada con el cáncer. La empresa emergente neerlandesa Cyclomics ha desarrollado una tecnología de detección de ADN tumoral circulante para la recidiva del cáncer de cabeza y cuello (CCC) que detecta mutaciones en el gen TP53. Su metodología de secuenciación innovadora permite una detección fiable, rápida y ultrasensible de la recidiva de este tipo de carcinoma a partir de muestras de sangre y biopsias líquidas. La mayoría de enfermos de CCC portan mutaciones de ADN específicas en el gen TP53, por lo que el empleo de esta tecnología constituye además una oportunidad de mercado notable para la empresa. El estudio de viabilidad del proyecto ONCOTECT, financiado con fondos europeos, permitirá obtener una perspectiva crítica de la estrategia de comercialización.
Objetivo
Cyclomics BV is a Dutch start-up company with the ambition to disrupt the cancer diagnostics market with its proprietary circulating tumor (ct) DNA detection technology. Cyclomics has developed a ground-breaking sequencing methodology that enables reliable, fast and ultra-sensitive detection of cancer recurrence from blood samples (liquid biopsies).
The first product, ONCOTECT, detects oncogenic mutations in the TP53 gene, and is developed for accurate and early detection of head and neck cancer (HNC) recurrence. Recurrent disease after initial remission is a main cause of cancer-related death. In HNC, radiological examination is the current standard in detecting cancer lesions but is unable to reliably detect recurrence early on, leading to treatment delays and lower survival rates. Integration of the ONCOTECT assay into routine clinical workflow is inexpensive and will provide faster time-to-results relative to competing sequencing methods.
Since 90% of HNC patients carry specific oncogenic DNA mutations in the TP53 gene, the first application of this novel technology in recurrent HNC presents a considerable market opportunity for ONCOTECT. After achieving clinical proof-of-concept in a cohort of 20 patients, Cyclomics will offer its technology for licensing to a diagnostics company to further develop ONCOTECT as an in vitro diagnostic (IVD) kit and bring it to the market, with the aim of enabling superior quality in diagnostic and clinical decision making. ONCOTECT focuses on TP53 but the underlying technology can be applied to many different genes. Leveraging this potential, Cyclomics’ long-term vision includes monitoring of cancer treatment response and early screening programs, encompassing various genes and cancer types, with the potential to impact the full spectrum of cancer care. In this SME feasibility study, Cyclomics will obtain critical insight for commercialization strategy, including freedom to operate (FTO), user needs and regulatory requirements.
Ámbito científico
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
3531 BX UTRECHT
Países Bajos
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.